Lyell Immunopharma reports Q2 2022 net loss of $36.3M; cash of $787M funds into 2025

Lyell Immunopharma, Inc.

2022-Q2 EPS reported -$0.43 revenue$36,294,000

Revenue of $35.7M (vs $2.6M YoY), driven by $35.3M from concluding GSK hematological cancer research.
Net loss GAAP $36.3M (vs $62.6M YoY); non-GAAP net loss $10.3M (vs $38.1M YoY).
R&D expense $43.7M (vs $46.4M YoY); G&A expense $30.5M (vs $19.1M YoY) due to stock compensation.
Cash, equivalents and marketable securities of $787.0M as of June 30, 2022, providing funding into 2025.
Lead CAR T candidate LYL797 on track for initial clinical data in 2023; preclinical data presented at ASGCT.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.